TScan Therapeutics (TCRX)
NASDAQ:TCRX
Want to see TCRX full AI Analyst Report?
TCRX Stock Chart & Stats
$1.19
-$0.17(-5.65%)
At close: 4:00 PM EST
$1.19
-$0.17(-5.65%)
Day’s Range― - ―
52-Week Range$0.88 - $2.57
Previous CloseN/A
Volume150.47K
Average Volume (3M)476.93K
Market Cap
$69.72M
Enterprise Value$5.93M
Total Cash (Recent Filing)$152.41M
Total Debt (Recent Filing)$94.14M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
May 12, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding55,824,722
10 Day Avg. Volume455,904
30 Day Avg. Volume476,927
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.05
Price to Sales (P/S)12.58
P/FCF Ratio-0.93
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue0.57
Enterprise Value/Gross Profit0.67
Enterprise Value/Ebitda-0.04
Forecast
1Y Price Target
$6.00Price Target Upside404.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$7.88M
Bulls Say, Bears Say
Bulls Say
Manufacturing Scale-up And Cell FitnessImplementation of a commercial-ready, shorter manufacturing process that reduces ex vivo T-cell expansion is intended to improve T-cell fitness and scalability, with Cohort C results able to show whether variability and relapse risk decline.
MRD Conversion And Donor ChimerismConversion of minimal residual disease positive patients to negative status combined with sustained donor chimerism is linked to lower relapse risk and supports TSC-101's potential to reshape post-transplant immune biology, strengthening a registrational case.
Regulatory Progress And Program ExpansionFDA clearance of investigational applications for additional TCR-T candidates and a planned pivotal study for TSC-101 expand the treatable patient population and indicate regulatory engagement with the development pathway.
Bears Say
Dose Optimization And Potency ChallengesPhase I experience showed limited potency for multi-plex constructs and weakening efficacy at higher dose cohorts, highlighting the risk that further dose optimization or process changes will be needed to achieve consistent clinical benefit.
Financial Runway And Dilution RiskCurrent cash burn and a constrained capital position create the risk that additional financing will be required, which could dilute shareholders and impede execution of the development plan.
Graft-versus-host Disease Safety RiskAcute graft-versus-host disease is a primary safety concern because any need to reintroduce immunosuppression would undermine the therapy's anti-leukemia effect and complicate clinical use.
TScan Therapeutics News
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $0.88 and its highest was $2.57 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $69.72M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is May 12, 2026 which is in 11 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on Mar 04, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.27 by $0.09.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.2.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 55,824,722 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.27. Following the earnings report the stock price went up 4.348%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (404.20% Upside)
$6.00 (404.20% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.8%
Last 30 Days ▲ 20.1%
Last 30 Days ▲ 20.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.14%
12-Months-Change
Fundamentals
Return on Equity
-79.36%
Trailing 12-Months
Asset Growth
-38.35%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$6.00
▲(404.20% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
19.12% Insiders
5.91% Mutual Funds
33.26% Other Institutional Investors
37.78% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---